Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical
company engaged in the commercialization and development of
innovative anti-infective agents to treat serious infections, today
announced its financial results for the three months ended March
31, 2020 and provided a corporate update.
“Aligned with the excellent managed care coverage we have
secured since launch, earlier this year Nabriva made the strategic
decision to refocus the XENLETA™ (lefamulin) commercial strategy to
the community setting. We are extremely pleased to report that
commercial and Medicare coverage from plans including Express
Scripts, United Health and CIGNA, representing in excess of 200
million patients or almost 70% of covered lives in the United
States, now have access to XENLETA,” said Ted Schroeder, Chief
Executive Officer of Nabriva Therapeutics.
“While the global pandemic has limited our ability to interact
in-person with health care providers, Nabriva initiated
non-personal promotional activities, leveraging digital platforms
as the primary means of providing clinicians product information
and education. Although it remains unclear when it will be deemed
safe to resume in-person promotional activities, we are actively
laying the foundation to be poised to launch our community-focused
sales effort as soon as it is practicable. In addition, we have
proactively taken steps to conserve our cash resources so that we
will be able to realize the full benefit from a strategic
investment in a community-focused sales effort at the appropriate
time. Through the judicious management of resources, we have been
able to extend our cash runway into the fourth quarter of 2020.”
Additional priorities for 2020 include:
- Obtaining approval of XENLETA in Europe and Canada;
- Obtaining approval of CONTEPO™ (fosfomycin for injection) in
the United States (U.S.);
- Executing on business development and licensing opportunities;
and
- Continuing to efficiently manage the balance sheet.
CORPORATE AND DEVELOPMENT
UPDATES
- Nabriva resubmitted the New Drug Application (NDA) for CONTEPO
to the U.S. Food and Drug Administration (FDA) on December 20, 2019
and the Prescription Drug User Fee Act (PDUFA) action date is June
19, 2020. Due to the COVID-19 pandemic, FDA has suspended travel
required to evaluate Nabriva’s manufacturing partners for CONTEPO.
Nabriva is actively working with the FDA to identify the most
expeditious manner to complete the review of the CONTEPO NDA.
CONTEPO is a novel, first-in-class intravenous investigational
antibiotic for the treatment of complicated urinary tract
infections, including pyelonephritis.
- COVID-19 has demonstrated the devastating impact that
infectious diseases can have on public health and the economy.
Similar to other acute respiratory virus infections, including
influenza virus, patients infected with SARS-CoV-2 are at increased
risk of developing concomitant bacterial pneumonia. In published
reports, bacterial pneumonia has been shown to affect nearly 50% of
hospitalized patients with COVID-19, with an associated mortality
of almost 50%. As a result, the World Health Organization currently
recommends empiric antimicrobials to treat all likely pathogens
causing severe acute respiratory infections and sepsis be given as
soon as possible in patients with COVID-19. XENLETA is approved for
the treatment of community-acquired bacterial pneumonia (CABP) in
adults in the United States. In addition to XENLETA’s potential
role in treating COVID-19 patients with superimposed bacterial
pneumonia, Nabriva is assessing the anti-inflammatory and antiviral
activity of XENLETA and what role, if any, these characteristics
may play in the management of patients with COVID-19.
- In recognition of the rising rates of bacterial resistance in
China and because CABP is commonly associated with acute
respiratory viruses infections, including influenza and
coronavirus, and based on XENLETA’s robust safety and efficacy data
in the treatment of patients with CABP generated globally and in
China, Nabriva’s collaborator, Sinovant is in active discussions
with China’s National Medical Products Administration to expedite
development activities and regulatory filings for lefamulin in
mainland China.
- In collaboration with the Global Antibiotic Research &
Development Partnership (GARD-P), Nabriva is assessing XENLETA for
the treatment of multi-drug resistant sexually transmitted
infections, including N. gonorrhoeae and M. genitalium. XENLETA has
been shown to possess potent in vitro activity against both
organisms, which is maintained in the presence of resistance to all
current standard of care treatment options (aminoglycoside,
cephalosporin, fluoroquinolone, macrolide, penicillin, and
tetracycline antibiotic classes). Importantly, XENLETA has been
shown to be bactericidal in vitro against both N. gonorrhoeae and
M. genitalium.
- The National Institute for Allergy and Infectious Diseases
(NIAID) has identified that secondary bacterial pneumonia caused by
common upper respiratory tract bacteria plays a predominant role in
the cause of death in pandemic influenza and recommends that the
prevention, diagnosis, prophylaxis, and treatment of secondary
bacterial pneumonia, as well as the stockpiling of antibiotics and
bacterial vaccines, be high priorities for pandemic planning. We
believe there is a potential for XENLETA to be considered for U.S.
government stockpiling for pandemic influenza.
- On March 11, 2020, Nabriva entered into an amendment to its
Loan and Security Agreement (Loan Agreement) with Hercules Capital,
Inc. Pursuant to the amendment, Nabriva repaid $30.0 million of the
$35.0 million in aggregate principal amount of debt outstanding
under the Loan Agreement to Hercules on March 20, 2020. The earlier
payback in March reduced interest expense in the first quarter. The
amendment also reset the revenue performance covenant under the
Loan Agreement to 70% of targeted revenue based on a revised net
product revenue forecast and lowered Nabriva’s minimum liquidity
requirement to $3.0 million in cash and cash equivalents
(previously $40.0 million), in each case, following the prepayment.
The new minimum liquidity requirement will not apply if CONTEPO
receives regulatory approval from the FDA and Nabriva achieves at
least 70% of its revised net product revenue targets under the Loan
Agreement.
- On April 7, 2020, Nabriva announced it was restructuring its
hospital-based commercial sales force and transitioning to a
community-based sales force. The restructuring aligns the
capabilities of the Company’s sales force with its strategic
refocus for promoting XENLETA to community health care
professionals, the excellent managed care coverage we have secured
and our business development strategy to in-license additional
community products, resulting in a substantial reduction in
expenditures. The restructuring resulted in the termination of 66
employees, consisting of the Company’s entire hospital-based sales
personnel and certain members of its sales force leadership team.
The restructuring of the sales force was timed, in part, to
coincide with operational changes that have been implemented by the
Company in response to the outbreak of the COVID-19. The Company
plans to utilize a sales force with community-based expertise to
replace its hospital-based sale force; however, the Company has not
determined when it will retain such a community-based sales team,
as it is currently unknown how long the operational restrictions
related to COVID-19 will remain in effect. The Company expects this
reduction in personnel to result in a savings of approximately $4.5
million in quarterly cash operating expenses beginning in the
second quarter of 2020 until the Company retains a community-based
sales force. In addition, the Company will incur a charge of
approximately $500,000 related to the reduction in personnel,
consisting of severance, benefits and related costs, all of which
will occur in the second quarter of 2020. Nabriva is also reducing
commercial, medical affairs and administrative expenses.
- On April 9, 2020, Nabriva received confirmation from the
Centers for Medicare and Medicaid Services (CMS) of a preliminary
decision to assign permanent product-specific Healthcare Common
Procedure Coding System (HCPCS) J-code for XENLETA 150 mg
injection. The new billing code, J0691 Injection, will become
effective July 1, 2020 and will replace the C Code, C9054.
Transitional pass-through status, previously granted in 2019, for
outpatient payments ends December 31, 2022. J-codes are used
by healthcare providers to list physician-administered drugs on
claim forms submitted to CMS to receive proper reimbursement for
Medicare-eligible patients. Having a unique J-code for XENLETA is
expected to help facilitate more efficient billing for hospitals
and assist in the tracking of XENLETA in claims
data.
- On April 29, 2020, Nabriva received written notice from NASDAQ
indicating that, based on the closing bid for the last 30
consecutive business days, the Company is not in compliance with
the $1.00 minimum bid price requirement for continued listing on
The Nasdaq Global Select Market. The Notice does not result in the
immediate delisting of the Company’s ordinary shares from The
Nasdaq Global Select Market. Nabriva will have until December 28,
2020 to regain compliance with the Bid Price Rule. To regain
compliance, the closing bid price of Nabriva’s ordinary shares must
be at least $1.00 per share for a minimum of ten consecutive
business days on or before December 28, 2020.
FINANCIAL RESULTS
Three Months Ended March 31, 2020 and 2019
- For the three months ended March 31, 2020, Nabriva Therapeutics
recorded revenues of $0.8 million, a $0.9 million decrease
compared to the three months ended March 31, 2019. The decrease was
primarily a result of a $0.9 million reduction in collaboration
revenue and $0.2 million reduction in grant revenue, partly offset
by $0.2 million increase in net product sales associated with the
launch of XENLETA. Nabriva reported a net loss of $23.3 million, or
$0.25 per share, for the three months ended March 31, 2020,
compared to a net loss of $20.2 million, or $0.29 per share, for
the three months ended March 31, 2019.
- Research and development expenses decreased by
$2.6 million from $7.5 million for the three months ended
March 31, 2019 to $4.9 million for the three months ended
March 31, 2020. The decrease was primarily due to a $3.0 million
reduction in research materials and purchased services related to
the development of XENLETA, a $1.2 million reduction in research
consulting fees and a $0.8 million reduction in staff costs, partly
offset by a $2.6 million refund of NDA filing fees for CONTEPO in
the first quarter of 2019.
- Selling, general and administrative expenses increased by
$2.6 million from $13.4 million for the three months
ended March 31, 2019 to $16.0 million for the three months
ended March 31, 2020. The increase was primarily due to a $3.5
million increase in staff costs due to the addition of employees
and a $0.2 million increase in travel and other corporate costs,
partly offset by $0.7 million reduction in advisory and external
consultancy expenses primarily related to pre-commercialization
activities and professional service fees in 2019, a $0.2 million
reduction in legal fees and a $0.2 million reduction in stock-based
compensation costs.
- As previously disclosed, Nabriva’s distribution partners
continue to primarily utilize their existing inventory to satisfy
product demand, which in turn impacted sales in the first quarter
of 2020. In light of the COVID-19 pandemic, the associated
disruption to the healthcare delivery and the uncertainty of
resuming direct physician medical education and promotion, future
sales amounts in 2020 are uncertain.
- As of March 31, 2020, Nabriva Therapeutics had $26.9 million in
cash and cash equivalents, compared to $86.0 million as of December
31, 2019. Nabriva repaid $30.0 million of the $35.0 million in
aggregate principal amount of debt outstanding under the Loan
Agreement to Hercules on March 20, 2020.
- Based on its current operating plans, the Company expects that
its existing cash resources will be sufficient to enable Nabriva to
fund its operating expenses, debt service obligations and capital
expenditure requirements into the fourth quarter of 2020. This
estimate assumes, among other things, that Nabriva remains in
compliance with the covenants under its Loan Agreement.
Please refer to our Annual Report on
Forms 10-K for the fiscal year ended December 31,
2019 and our Quarterly Report on Form 10-Q for the quarterly period
ended March 31, 2020, which are filed with the U.S. Securities and
Exchange Commission, for additional information regarding the
Company’s business and financial results.
Company to Host Conference Call
Nabriva’s management will host a conference call today at 4:30
p.m. ET to discuss the financial results and recent corporate
highlights. The dial-in number for the conference call is (866)
811-8671 for domestic participants and (409) 981-0874 for
international participants, with Conference ID #1693918. A
live webcast of the conference call can be accessed through the
“Investors” tab on the Nabriva Therapeutics website at
www.nabriva.com. A replay will be available on this website shortly
after conclusion of the event for 90 days.
About Nabriva Therapeutics
plc
Nabriva Therapeutics is a biopharmaceutical
company engaged in the commercialization and development of
innovative anti-infective agents to treat serious infections.
Nabriva Therapeutics received U.S. Food and Drug Administration
approval for XENLETA™ (lefamulin injection, lefamulin tablets), the
first systemic pleuromutilin antibiotic for community-acquired
bacterial pneumonia (CABP). Nabriva Therapeutics is also developing
CONTEPO™ (fosfomycin) for injection, a potential first-in-class
epoxide antibiotic for complicated urinary tract infections
(cUTIs), including acute pyelonephritis. For more information,
please visit www.nabriva.com.
About XENLETA
XENLETA (lefamulin) is a first-in-class semi-synthetic
pleuromutilin antibiotic for systemic administration in humans
discovered and developed by the Nabriva Therapeutics team. It is
designed to inhibit the synthesis of bacterial protein, which is
required for bacteria to grow. XENLETA’s binding occurs with high
affinity, high specificity and at molecular sites that are
different than other antibiotic classes. Efficacy of XENLETA was
demonstrated in two multicenter, multinational, double-blind,
double-dummy, non-inferiority trials assessing a total of 1,289
patients with CABP. In these trials, XENLETA was compared
with moxifloxacin and in one trial, moxifloxacin with and without
linezolid. Patients who received XENLETA had similar rates of
efficacy as those taking moxifloxacin alone or moxifloxacin plus
linezolid. The most common adverse reactions associated with
XENLETA included diarrhea, nausea, reactions at the injection site,
elevated liver enzymes, and vomiting. For more information, please
visit www.xenleta.com.
INDICATION AND IMPORTANT SAFETY INFORMATION
INDICATION
XENLETA is a pleuromutilin antibacterial indicated for the
treatment of adults with community-acquired bacterial pneumonia
(CABP) caused by the following susceptible microorganisms:
Streptococcus pneumoniae, Staphylococcus aureus
(methicillin-susceptible isolates), Haemophilus influenzae,
Legionella pneumophila, Mycoplasma pneumoniae, and Chlamydophila
pneumoniae.
USAGE
To reduce the development of drug-resistant bacteria and
maintain the effectiveness of XENLETA and other antibacterial
drugs, XENLETA should be used only to treat or prevent infections
that are proven or strongly suspected to be caused by susceptible
bacteria.
IMPORTANT SAFETY INFORMATION
CONTRAINDICATIONS
XENLETA is contraindicated in patients with known
hypersensitivity to XENLETA or pleuromutilins.XENLETA tablets are
contraindicated for use with CYP3A4 substrates that prolong the QT
interval.
WARNINGS AND PRECAUTIONS
XENLETA has the potential to prolong the QT interval. Avoid
XENLETA in patients with known QT prolongation, ventricular
arrhythmias, and patients receiving drugs that may prolong the QT
interval.Based on animal studies, XENLETA may cause fetal harm.
Advise females of reproductive potential of the potential risk to
the fetus and to use effective contraception.Clostridium
difficile-associated diarrhea (CDAD) has been reported with nearly
all systemic antibacterial agents, including XENLETA, with severity
ranging from mild diarrhea to fatal colitis. Evaluate if diarrhea
occurs.
ADVERSE REACTIONS
The most common adverse reactions (≥2%) for (a) XENLETA
Injection are administration site reactions, hepatic enzyme
elevation, nausea, hypokalemia, insomnia, and headache and (b)
XENLETA Tablets are diarrhea, nausea, vomiting, and hepatic enzyme
elevation.
USE IN SPECIFIC POPULATIONS
In patients with severe hepatic impairment, reduce the dosage of
XENLETA Injection to 150 mg infused over 60 minutes every 24 hours.
XENLETA Tablets are not recommended in patients with moderate or
severe hepatic impairment due to insufficient information to
provide dosing recommendations.Avoid XENLETA Injection and Tablets
with concomitant strong or moderate CYP3A or P-gp inducers. Monitor
for reduced efficacy of XENLETA.Avoid XENLETA Tablets with strong
CYP3A or P-gp inhibitors.Monitor for adverse reactions of sensitive
CYP3A substrates administered with XENLETA Tablets.XENLETA has not
been studied in pregnant women. Verify pregnancy status in females
prior to initiating XENLETA and advise females to use contraception
during treatment and for 2 days after the final dose. Lactating
women should pump and discard milk for the duration of treatment
with XENLETA and for 2 days after the final dose.To report
SUSPECTED ADVERSE REACTIONS, or administration during pregnancy,
contact Nabriva Therapeutics US, Inc. at 1-855-5NABRIVA or FDA at
1-800-FDA-1088 or https://www.fda.gov/safety/medwatch.
Please see Full Prescribing Information for
XENLETA.
Forward-Looking Statements
Any statements in this press release about future expectations,
plans and prospects for Nabriva Therapeutics, including but not
limited to statements about its ability to successfully launch and
commercialize XENLETA for the treatment of CABP, including
the availability of and ease of access to XENLETA through major
U.S. specialty distributors, marketing exclusivity and patent
protection for XENLETA, the development of CONTEPO for cUTI, the
clinical utility of XENLETA for CABP and of CONTEPO for cUTI, plans
for and timing of the review of regulatory filings for CONTEPO,
efforts to bring CONTEPO to market, the market opportunity for and
the potential market acceptance of XENLETA for CABP and CONTEPO for
cUTI, the development of XENLETA and CONTEPO for additional
indications, the development of additional formulations of XENLETA
and CONTEPO, plans for making lefamulin available in China, plans
to pursue research and development of other product candidates,
ability to regain compliance with the Nasdaq listing standards,
expectations regarding the ability of customers to satisfy demand
for XENLETA with their existing inventory, the sufficiency of
Nabriva Therapeutics’ existing cash resources and its expectations
regarding anticipated revenues from product sales and how far into
the future its existing cash resources will fund its ongoing
operations and other statements containing the words “anticipate,”
“believe,” “estimate,” “expect,” “intend,” “may,” “plan,”
“predict,” “project,” “target,” “potential,” “likely,” “will,”
“would,” “could,” “should,” “continue,” and similar expressions,
constitute forward-looking statements within the meaning of The
Private Securities Litigation Reform Act of 1995. Actual results
may differ materially from those indicated by such forward-looking
statements as a result of various important factors, including:
Nabriva Therapeutics’ ability to successfully implement its
commercialization plans for XENLETA and whether market demand for
XENLETA is consistent with its expectations, Nabriva Therapeutics’
ability to build and maintain a sales force for XENLETA, the
content and timing of decisions made by the U.S. Food and Drug
Administration and other regulatory authorities, the uncertainties
inherent in the initiation and conduct of clinical trials,
availability and timing of data from clinical trials, whether
results of early clinical trials or studies in different disease
indications will be indicative of the results of ongoing or future
trials, uncertainties associated with regulatory review of clinical
trials and applications for marketing approvals, the availability
or commercial potential of CONTEPO for the treatment of cUTI, the
extent of business interruptions resulting from the infection
causing the COVID-19 outbreak or similar public health crises, the
ability to retain and hire key personnel, the availability of
adequate additional financing on acceptable terms or at all and
such other important factors as are set forth in Nabriva
Therapeutics’ annual and quarterly reports and other filings on
file with the U.S. Securities and Exchange Commission. In addition,
the forward-looking statements included in this press release
represent Nabriva Therapeutics’ views as of the date of this press
release. Nabriva Therapeutics anticipates that subsequent events
and developments will cause its views to change. However, while
Nabriva Therapeutics may elect to update these forward-looking
statements at some point in the future, it specifically disclaims
any obligation to do so. These forward-looking statements should
not be relied upon as representing Nabriva Therapeutics’ views as
of any date subsequent to the date of this press release.
CONTACTS:
For InvestorsGary SenderNabriva Therapeutics
plcir@nabriva.com
For MediaMike BeyerSam Brown Inc.
mikebeyer@sambrown.com312-961-2502
|
Consolidated
Balance Sheets(unaudited) |
|
(in thousands, except share data) |
|
As of December 31, 2019 |
|
|
As of March 31, 2020 |
|
|
|
|
|
|
Assets |
|
|
|
|
|
Current assets: |
|
|
|
|
|
Cash and cash equivalents |
|
$ |
86,019 |
|
|
$ |
26,938 |
|
Restricted cash |
|
392 |
|
|
444 |
|
Short-term investments |
|
175 |
|
|
175 |
|
Accounts receivable, net and other receivables |
|
2,744 |
|
|
3,467 |
|
Inventory |
|
682 |
|
|
4,224 |
|
Prepaid expenses |
|
1,158 |
|
|
2,925 |
|
Total current assets |
|
91,170 |
|
|
38,173 |
|
Property, plant and equipment,
net |
|
2,474 |
|
|
2,340 |
|
Intangible assets, net |
|
91 |
|
|
111 |
|
Long-term receivables |
|
378 |
|
|
378 |
|
Total assets |
|
$ |
94,113 |
|
|
$ |
41,002 |
|
|
|
|
|
|
|
|
|
|
Liabilities and
equity |
|
|
|
|
|
|
|
|
Current liabilities: |
|
|
|
|
|
Accounts payable |
|
$ |
4,673 |
|
|
$ |
2,033 |
|
Accrued expense and other current liabilities |
|
11,966 |
|
|
9,929 |
|
Total current liabilities |
|
16,639 |
|
|
11,962 |
|
Non-current
liabilities |
|
|
|
|
|
Long-term debt |
|
34,502 |
|
|
7,374 |
|
Other non-current liabilities |
|
1,698 |
|
|
1,752 |
|
Total non-current liabilities |
|
36,200 |
|
|
9,126 |
|
Total liabilities |
|
52,839 |
|
|
21,088 |
|
Stockholders’ Equity: |
|
|
|
|
|
|
|
|
Ordinary shares, nominal value $0.01, 1,000,000,000 ordinary shares
authorized at March 31, 2020; 94,545,116 and 95,109,047 issued
and outstanding at December 31, 2019 and March 31, 2020,
respectively |
|
945 |
|
|
951 |
|
|
|
|
|
|
|
|
Preferred shares, par value $0.01, 100,000,000 shares authorized at
March 31, 2020; None issued and outstanding |
|
— |
|
|
— |
|
Additional paid in capital |
|
517,044 |
|
|
518,937 |
|
Accumulated other comprehensive income |
|
27 |
|
|
27 |
|
Accumulated deficit |
|
(476,742 |
) |
|
(500,001 |
) |
Total stockholders’ equity |
|
41,274 |
|
|
19,914 |
|
Total liabilities and stockholders’
equity |
|
$ |
94,113 |
|
|
$ |
41,002 |
|
|
|
|
|
|
|
|
|
|
Consolidated Statements of
Operations(unaudited) |
|
|
|
Three Months Ended March 31, |
|
(in thousands, except share and per share data) |
|
2019 |
|
|
2020 |
|
Revenues: |
|
|
|
|
|
|
Product revenue, net |
|
$ |
— |
|
|
$ |
156 |
|
Collaboration revenue |
|
1,000 |
|
|
145 |
|
Research premium and grant revenue |
|
703 |
|
|
488 |
|
Total revenue |
|
1,703 |
|
|
789 |
|
Operating
expenses: |
|
|
|
|
|
|
Cost of product sales |
|
— |
|
|
(8 |
) |
Research and development expenses |
|
(7,538 |
) |
|
(4,944 |
) |
Selling, general and administrative expenses |
|
(13,409 |
) |
|
(16,025 |
) |
Total operating expenses |
|
(20,947 |
) |
|
(20,977 |
) |
Loss from
operations |
|
(19,244 |
) |
|
(20,188 |
) |
Other income
(expense): |
|
|
|
|
|
|
Other income (expense), net |
|
70 |
|
|
798 |
|
Interest income |
|
10 |
|
|
64 |
|
Interest expense |
|
(899 |
) |
|
(1,024 |
) |
Loss on extinguishment of debt |
|
— |
|
|
(2,757 |
) |
Loss before income taxes |
|
(20,063 |
) |
|
(23,107 |
) |
Income tax expense |
|
(154 |
) |
|
(152 |
) |
Net loss |
|
$ |
(20,217 |
) |
|
$ |
(23,259 |
) |
|
|
|
|
|
|
|
Loss per share |
|
|
|
|
|
|
Basic and Diluted ($ per
share) |
|
$ |
(0.29 |
) |
|
$ |
(0.25 |
) |
|
|
|
|
|
|
|
Weighted average
number of shares: |
|
|
|
|
|
|
Basic and Diluted |
|
68,701,599 |
|
|
94,595,152 |
|
|
|
|
|
|
|
|
|
|
Condensed Consolidated Statements of Cash
Flows(unaudited) |
|
|
|
|
|
|
Three Months Ended March 31, |
|
(in thousands) |
|
|
2019 |
|
|
|
2020 |
|
Net cash
provided by (used in): |
|
|
|
|
|
|
|
|
Operating
activities |
|
$ |
(20,625 |
) |
|
$ |
(28,108 |
) |
Investing
activities |
|
|
(42 |
) |
|
|
(20 |
) |
Financing
activities |
|
|
9,679 |
|
|
|
(30,219 |
) |
Effects of foreign
currency translation on cash and cash equivalents |
|
|
27 |
|
|
|
(682 |
) |
Net decrease in cash,
cash equivalents and restricted cash |
|
|
(10,961 |
) |
|
|
(59,029 |
) |
Cash, cash
equivalents and restricted cash at beginning of quarter |
|
|
102,003 |
|
|
|
86,411 |
|
Cash, cash
equivalents and restricted cash at end of quarter |
|
$ |
91,042 |
|
|
$ |
27,382 |
|
|
|
|
|
|
|
|
|
|
Nabriva Therapeutics (NASDAQ:NBRV)
Historical Stock Chart
From Mar 2024 to Apr 2024
Nabriva Therapeutics (NASDAQ:NBRV)
Historical Stock Chart
From Apr 2023 to Apr 2024